Gain Therapeutics Inc. (GANX) is a clinical-stage biotechnology company advancing next-generation allosteric therapies for neurodegenerative and rare diseases. Its lead candidate, GT-02287, is in clinical development for Parkinson's disease with or without a GBA1 mutation, supported by promising preclinical and early clinical data. With enrollment completed in its Phase 1b study and multiple upcoming milestones, Gain is positioned for important readouts that could shape its trajectory in 2026.
Stock Performance
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com